Obeticholic acid for the treatment of primary biliary cirrhosis

Palak J. Trivedi, Gideon M. Hirschfield, M. Eric Gershwin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.

Original languageEnglish (US)
Pages (from-to)13-26
Number of pages14
JournalExpert Review of Clinical Pharmacology
Volume9
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Biliary Liver Cirrhosis
Intrahepatic Cholestasis
Ursodeoxycholic Acid
End Stage Liver Disease
Poisons
Cholestasis
Pruritus
Cytoplasmic and Nuclear Receptors
Bile Ducts
Bile Acids and Salts
Regeneration
Fibrosis
Ligands
Safety
Survival
Liver
Therapeutics
6-ethylchenodeoxycholic acid

Keywords

  • autoimmune disease
  • cholangitis
  • obeticholic acid
  • primary biliary cirrhosis
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Obeticholic acid for the treatment of primary biliary cirrhosis. / Trivedi, Palak J.; Hirschfield, Gideon M.; Gershwin, M. Eric.

In: Expert Review of Clinical Pharmacology, Vol. 9, No. 1, 02.01.2016, p. 13-26.

Research output: Contribution to journalArticle

Trivedi, Palak J. ; Hirschfield, Gideon M. ; Gershwin, M. Eric. / Obeticholic acid for the treatment of primary biliary cirrhosis. In: Expert Review of Clinical Pharmacology. 2016 ; Vol. 9, No. 1. pp. 13-26.
@article{bd27716a0be64a78893869721ebe0c1b,
title = "Obeticholic acid for the treatment of primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.",
keywords = "autoimmune disease, cholangitis, obeticholic acid, primary biliary cirrhosis, ursodeoxycholic acid",
author = "Trivedi, {Palak J.} and Hirschfield, {Gideon M.} and Gershwin, {M. Eric}",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/17512433.2015.1092381",
language = "English (US)",
volume = "9",
pages = "13--26",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Obeticholic acid for the treatment of primary biliary cirrhosis

AU - Trivedi, Palak J.

AU - Hirschfield, Gideon M.

AU - Gershwin, M. Eric

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.

AB - Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.

KW - autoimmune disease

KW - cholangitis

KW - obeticholic acid

KW - primary biliary cirrhosis

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84949095927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949095927&partnerID=8YFLogxK

U2 - 10.1586/17512433.2015.1092381

DO - 10.1586/17512433.2015.1092381

M3 - Article

VL - 9

SP - 13

EP - 26

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 1

ER -